Edition:
United States

vTv Therapeutics Inc (VTVT.OQ)

VTVT.OQ on NASDAQ Stock Exchange Global Market

1.47USD
20 Jul 2018
Change (% chg)

$0.01 (+0.68%)
Prev Close
$1.46
Open
$1.48
Day's High
$1.49
Day's Low
$1.44
Volume
9,606
Avg. Vol
233,544
52-wk High
$8.37
52-wk Low
$0.65

Latest Key Developments (Source: Significant Developments)

Vtv Therapeutics Announces Topline Results From The First Steadfast Phase 3 Study Evaluating Azeliragon In People With Mild Alzheimer's Disease
Monday, 9 Apr 2018 04:46pm EDT 

April 9 (Reuters) - vTv Therapeutics Inc ::VTV THERAPEUTICS ANNOUNCES TOPLINE RESULTS FROM THE FIRST STEADFAST PHASE 3 STUDY EVALUATING AZELIRAGON IN PEOPLE WITH MILD ALZHEIMER’S DISEASE.VTV THERAPEUTICS INC - AZELIRAGON WAS GENERALLY WELL-TOLERATED IN STUDY.VTV THERAPEUTICS INC - PHASE 3 STEADFAST STUDY DID NOT MEET EITHER CO-PRIMARY EFFICACY ENDPOINT.VTV THERAPEUTICS - IS DISCONTINUING CURRENT CLINICAL STUDIES INVOLVING AZELIRAGON, INCLUDING OPEN-LABEL EXTENSION STUDY AND PART B OF STEADFAST STUDY​.VTV THERAPEUTICS - WILL CONTINUE TO EVALUATE SUBSET DATA FROM PART A AND DATASET FROM PART B OF STEADFAST STUDY OVER COMING WEEKS.VTV THERAPEUTICS - EXPECT SUBSTANTIAL PORTION OF PATIENTS IN PART B OF STEADFAST WILL HAVE COMPLETED 12 MONTHS OF TREATMENT UNDER STUDY PROTOCOL.  Full Article

vTv Therapeutics Files For Stock Shelf Of Up To $250 Million
Tuesday, 27 Feb 2018 05:20pm EST 

Feb 27 (Reuters) - vTv Therapeutics Inc ::VTV THERAPEUTICS INC FILES FOR STOCK SHELF OF UP TO $250 MILLION – SEC FILING‍​.  Full Article

VTV Therapeutics Reports Q4 Loss Per Share $0.44
Tuesday, 27 Feb 2018 05:15pm EST 

Feb 27 (Reuters) - VTV Therapeutics Inc ::VTV THERAPEUTICS REPORTS 2017 FOURTH QUARTER AND FULL YEAR FINANCIAL AND OPERATIONAL RESULTS AND RECENT HIGHLIGHTS.Q4 GAAP LOSS PER SHARE $0.44.QTRLY NON-GAAP NET LOSS PER FULLY EXCHANGED SHARE WAS $0.44.  Full Article

Vtv Therapeutics, Reneo Pharmaceuticals Enter Licensing Agreement
Thursday, 21 Dec 2017 04:30pm EST 

Dec 21 (Reuters) - Vtv Therapeutics Inc ::VTV THERAPEUTICS AND RENEO PHARMACEUTICALS ENTER LICENSING AGREEMENT FOR PPAR-DELTA PROGRAM.VTV THERAPEUTICS INC - UNDER TERMS OF AGREEMENT, VTV THERAPEUTICS WILL RECEIVE AN UPFRONT PAYMENT.VTV THERAPEUTICS INC - UNDER TERMS OF AGREEMENT, VTV THERAPEUTICS WILL ALSO RECEIVE SHARES OF RENEO PHARMACEUTICALS' COMMON STOCK.  Full Article

vTv Therapeutics Signs Agreement With Hangzhou Zhongmei For Rights of Glp-1R Agonist Diabetes Program
Thursday, 21 Dec 2017 03:00am EST 

Dec 21 (Reuters) - vTv Therapeutics Inc ::VTV THERAPEUTICS INC SAYS LICENSING AGREEMENT WITH HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO. TO RIGHTS FOR VTV'S GLP-1R AGONIST DIABETES PROGRAM.VTV THERAPEUTICS-GRANTED HUADONG PHARMACEUTICAL EXCLUSIVE LICENSE TO DEVELOP, COMMERCIALIZE GLP-1R AGONIST PROGRAM IN CHINA, HK, AND OTHER COUNTRIES.VTV THERAPEUTICS INC SAYS WILL RECEIVE AN $8 MILLION UPFRONT PAYMENT AND IS ELIGIBLE FOR UP TO AN ADDITIONAL $75 MILLION IN MILESTONE PAYMENTS.  Full Article

VTv Therapeutics Entered Into Agreement With MacAndrews & Forbes
Wednesday, 6 Dec 2017 06:21am EST 

Dec 6 (Reuters) - Vtv Therapeutics Inc ::VTV THERAPEUTICS SAYS ON DEC 5, CO ENTERED INTO A LETTER AGREEMENT WITH MACANDREWS & FORBES GROUP LLC - SEC FILING.VTV THERAPEUTICS INC - ENTERED AGREEMENT FOR INVESTOR'S COMMITMENT TO PURCHASE, CO'S CLASS A COMMON STOCK AT $4.38/SHARE.VTV THERAPEUTICS INC - AMOUNT OF COMMON STOCK THAT MAY BE PURCHASED BY INVESTOR PURSUANT TO LETTER AGREEMENT IS LIMITED TO $10.0 MILLION.  Full Article

vTv Therapeutics reports Q3 GAAP loss per share of $0.38
Wednesday, 1 Nov 2017 04:30pm EDT 

Nov 1 (Reuters) - Vtv Therapeutics Inc ::vTv Therapeutics reports third quarter 2017 financial and operational results.Q3 GAAP loss per share $0.38.Q3 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S.Qtrly ‍non-GAAP net loss per fully exchanged share was $0.38​.Research and development expenses were $9.0 million in Q3 of 2017, compared to $9.6 million in Q2 of 2017​.  Full Article

JDRF, VTV Therapeutics collaborate on Phase 2 study of novel treatment for type 1 diabetes
Wednesday, 6 Sep 2017 07:00am EDT 

Sept 6 (Reuters) - VTV Therapeutics Inc :JDRF and VTV Therapeutics announce collaboration on Phase 2 study of novel treatment for Type 1 diabetes.VTV Therapeutics Inc - JDRF has committed $3 million to study, and VTV will contribute an equal amount.VTV Therapeutics - study is designed to evaluate whether TTP399 is well tolerated when administered as an add-on to insulin therapy for people with T1D.  Full Article

vTv Therapeutics Q2 loss per share $0.41
Wednesday, 2 Aug 2017 04:30pm EDT 

Aug 2 (Reuters) - vTv Therapeutics Inc :vTv Therapeutics reports second quarter 2017 financial and operational results.Q2 gaap loss per share $0.41.Q2 earnings per share view $-0.43 -- Thomson Reuters I/B/E/S.vTv Therapeutics Inc - ‍cash and cash equivalents as of june 30, 2017 were $32.5 million compared to $45.2 million as of March 31, 2017​.vTv Therapeutics Inc - ‍expects cash, cash equivalents will be sufficient to fund its operations through to early 2018​.vTv Therapeutics Inc - ‍expected to report top-line results from part A and B of steadfast study in early 2018 and late 2018, respectively​.  Full Article

VTV Therapeutics completes enrollment of part B of pivotal phase III steadfast trial evaluating Azeliragon
Thursday, 1 Jun 2017 07:00am EDT 

June 1 (Reuters) - Vtv Therapeutics Inc :VTV Therapeutics completes enrollment of part B of pivotal phase III steadfast trial evaluating Azeliragon for the treatment of patients with mild alzheimer’s disease.VTV Therapeutics completes enrollment of part B of pivotal phase III steadfast trial evaluating Azeliragon for the treatment of patients with mild alzheimer’s disease.VTV Therapeutics - ‍phase 2B results of 5mg per day of azeliragon over period of 18 months showed statistically significant benefit in mild-to-moderate alzheimer's patients​.  Full Article

BRIEF-vTv Therapeutics Q1 GAAP Loss Per Share $0.30

* VTV THERAPEUTICS REPORTS 2018 FIRST QUARTER FINANCIAL AND OPERATIONAL RESULTS AND RECENT HIGHLIGHTS